Nasdaq · CIK 0000275053
NATR NATURES SUNSHINE PRODUCTS INC
Insider trading from SEC Form 4. Last filing 26 d ago. Close $12.64 on Oct 9, 2026, +2% from the 52-week low and -55% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
NATROct 9, 2026 · close 12.64
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NATURES SUNSHINE PRODUCTS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner sell | $30k 2,300 shares | -3% | - | |
| 28Weak | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner sell | $145k 10,895 shares | -14% | - |
Transactions
The last 25 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Ruth Ann Perkins EVP, Chief Financial Officer | AGrant or award Common Shares | +39,384 | $0.00 | $0 | 39,384 | 26 d ago |
| Sep 2, 2026 | Ruth Ann Perkins EVP, Chief Financial Officer | AGrant or award Common Shares | +36,049 | $0.00 | $0 | 75,433 | 26 d ago |
| Sep 1, 2026 | Jonathan David Lanoy SVP, Chief Accounting Officer | AGrant or award Common Shares | +7,210 | $0.00 | $0 | 55,602 | 38 d ago |
| Mar 10, 2025 | Kevin R. Herbert EVP & President, North America | AGrant or award Common Shares | +11,760 | $14.74 | $173k | 43,595 | Mar 12, 2025 |
| Mar 10, 2025 | Leslie Shane Jones EVP & Chief Financial Officer | AGrant or award Common Shares | +19,474 | $14.74 | $287k | 108,687 | Mar 12, 2025 |
| Mar 10, 2025 | Martin A. Gonzalez EVP, Global Supply Chain | AGrant or award Common Shares | +13,758 | $14.74 | $203k | 70,589 | Mar 12, 2025 |
| Mar 10, 2025 | Kevin Gregory Fuller Global Chief Marketing Officer | AGrant or award Common Shares | +13,148 | $14.74 | $194k | 24,218 | Mar 12, 2025 |
| Mar 10, 2025 | Tracee Comstock VP, Human Resources | AGrant or award Common Shares | +8,890 | $14.74 | $131k | 66,518 | Mar 12, 2025 |
| Mar 10, 2025 | Nathan G Brower EVP, General Counsel | AGrant or award Common Shares | +11,966 | $14.74 | $176k | 60,755 | Mar 12, 2025 |
| Mar 11, 2025 | Leslie Shane Jones EVP & Chief Financial Officer | FTax withholding Common Shares | -2,343 | $14.50 | $34k | 106,344 | Mar 12, 2025 |
| Mar 11, 2025 | Kevin R. Herbert EVP & President, North America | FTax withholding Common Shares | -980 | $14.50 | $14k | 42,615 | Mar 12, 2025 |
| Mar 11, 2025 | Martin A. Gonzalez EVP, Global Supply Chain | FTax withholding Common Shares | -1,290 | $14.50 | $19k | 69,299 | Mar 12, 2025 |
| Mar 11, 2025 | Tracee Comstock VP, Human Resources | FTax withholding Common Shares | -834 | $14.50 | $12k | 65,684 | Mar 12, 2025 |
| Mar 11, 2025 | Nathan G Brower EVP, General Counsel | FTax withholding Common Shares | -991 | $14.50 | $14k | 59,764 | Mar 12, 2025 |
| Dec 19, 2024 | Leslie Shane Jones EVP & Chief Financial Officer | AGrant or award Common Shares | -9,925 | $15.13 | $150k | 89,213 | Dec 26, 2024 |
| Nov 27, 2024 | Daniel C Norman EVP & President, Asia | GGift Common Shares | -3,600 | $16.44 | $59k | 59,176 | Dec 4, 2024 |
| Nov 11, 2024 | Steven J. Fasching director | AGrant or award Common Shares | +2,869 | $17.43 | $50k | 2,869 | Nov 13, 2024 |
| Oct 15, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | SOpen-market sale Common Stockindirect: by Fosun Industrial Co., Limited | -2,300 | $13.02 | $30k | 64,167 | Oct 17, 2024 |
| Sep 6, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | JOther Common Stockindirect: by Fosun Industrial Co., Limited | +2,968 | $0.00 | $0 | 77,362 | Oct 15, 2024 |
| Oct 1, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | SOpen-market sale Common Stockindirect: by Fosun Industrial Co., Limited | -1,399 | $13.54 | $19k | 75,963 | Oct 15, 2024 |
| Oct 8, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | SOpen-market sale Common Stockindirect: by Fosun Industrial Co., Limited | -1,800 | $13.13 | $24k | 74,163 | Oct 15, 2024 |
| Oct 9, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | SOpen-market sale Common Stockindirect: by Fosun Industrial Co., Limited | -1,816 | $13.36 | $24k | 72,347 | Oct 15, 2024 |
| Oct 10, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | SOpen-market sale Common Stockindirect: by Fosun Industrial Co., Limited | -3,000 | $13.39 | $40k | 69,347 | Oct 15, 2024 |
| Oct 11, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | SOpen-market sale Common Stockindirect: by Fosun Industrial Co., Limited | -1,580 | $13.37 | $21k | 67,767 | Oct 15, 2024 |
| Oct 14, 2024 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. owner | SOpen-market sale Common Stockindirect: by Fosun Industrial Co., Limited | -1,300 | $13.12 | $17k | 66,467 | Oct 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Nathan G BrowerEVP, General Counsel
- Tracee ComstockVP, Human Resources
- Steven J. Faschingcfo, officer, director
- Kevin Gregory FullerGlobal Chief Marketing Officer
- Martin A. GonzalezEVP, Global Supply Chain
- Kevin R. HerbertEVP & President, North America
- Leslie Shane JonesEVP & Chief Financial Officer
- Jonathan David LanoySVP, Chief Accounting Officer
- Daniel C NormanEVP & President, Asia
- Ruth Ann PerkinsEVP, Chief Financial Officer
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.